These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. Suzuki-Inoue K; Osada M; Ozaki Y J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039 [TBL] [Abstract][Full Text] [Related]
8. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532 [TBL] [Abstract][Full Text] [Related]
9. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI. Ozaki Y; Suzuki-Inoue K; Inoue O J Thromb Haemost; 2009 Jul; 7 Suppl 1():191-4. PubMed ID: 19630798 [TBL] [Abstract][Full Text] [Related]
10. Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis. Inoue O; Hokamura K; Shirai T; Osada M; Tsukiji N; Hatakeyama K; Umemura K; Asada Y; Suzuki-Inoue K; Ozaki Y PLoS One; 2015; 10(9):e0139357. PubMed ID: 26418160 [TBL] [Abstract][Full Text] [Related]
11. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction. Yuan Y; Dopheide SM; Ivanidis C; Salem HH; Jackson SP J Biol Chem; 1997 Aug; 272(35):21847-54. PubMed ID: 9268316 [TBL] [Abstract][Full Text] [Related]
12. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Suzuki-Inoue K Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548 [TBL] [Abstract][Full Text] [Related]
13. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Suzuki-Inoue K Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):175-181. PubMed ID: 31808911 [TBL] [Abstract][Full Text] [Related]
14. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501 [TBL] [Abstract][Full Text] [Related]
15. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756 [TBL] [Abstract][Full Text] [Related]
17. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030 [TBL] [Abstract][Full Text] [Related]
18. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis. Sheng M; Sun R; Fu J; Lu G BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690 [TBL] [Abstract][Full Text] [Related]
19. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Alevriadou BR; Moake JL; Turner NA; Ruggeri ZM; Folie BJ; Phillips MD; Schreiber AB; Hrinda ME; McIntire LV Blood; 1993 Mar; 81(5):1263-76. PubMed ID: 8443388 [TBL] [Abstract][Full Text] [Related]